Global Health Limited (MEDANTA) AI Stock Analysis

• Market Cap: ₹376.17B
• Dividend Yield: 0.04%
• Average Volume (3M): 16.66K
• Price to Earnings (P/E): 70.4
• Beta (1Y): 0.46
• Revenue Growth: 15.42%
• EPS Growth: 10.66%
• Country: IN
• Employees: 9,052
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Care Facilities
• EPS (TTM): 5.60
• Shares Outstanding: 268,770,400
• 10 Day Avg. Volume: 12,714
• 30 Day Avg. Volume: 16,660
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,453.60
• Price Target Upside: 3.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 75 Outperform
• Price Target: ₹1,598.00 ▲(14.22% Upside)

Global Health Limited's strong financial performance is the most significant factor, supported by robust revenue and profit growth and a stable balance sheet. Technical analysis shows positive momentum, though caution is advised due to overbought signals. The high P/E ratio suggests potential overvaluation, impacting the overall score.

Global Health Limited Business Overview & Revenue Model

Company Description

Global Health Limited, operating under the brand name MEDANTA, is a prominent healthcare organization based in India. It specializes in providing comprehensive healthcare services across various medical disciplines. MEDANTA's core offerings include multi-specialty medical care, cutting-edge diagnostic services, and advanced surgical procedures, supported by a team of experienced healthcare professionals and state-of-the-art facilities.

How the Company Makes Money

MEDANTA generates revenue primarily through its healthcare services, including inpatient and outpatient care. The company offers a wide range of medical treatments and procedures, attracting patients both domestically and internationally. Revenue streams include hospital services, diagnostic and laboratory services, as well as specialized medical procedures. Additionally, MEDANTA may engage in partnerships with insurance companies to facilitate patient care and reimbursements, further contributing to its financial performance.

Global Health Limited Financial Statement Overview

Summary

Global Health Limited exhibits strong financial health with impressive revenue and profit growth, efficient operations, and a stable balance sheet with prudent leverage. While cash flow management is generally positive, fluctuations in free cash flow warrant attention.

Income Statement

Global Health Limited has demonstrated robust revenue growth with a consistent increase over the years, notably a 12.74% increase from 2024 to 2025. The gross profit margin remains strong, reflecting efficient cost management. The net profit margin has improved slightly, indicating enhanced profitability. The company shows strong EBIT and EBITDA margins, suggesting efficient operations and a healthy operating profit.

Balance Sheet

The company maintains a solid balance sheet with a favorable debt-to-equity ratio of 0.21, indicating prudent leverage management. The return on equity (ROE) is strong at 14.21%, showcasing effective use of equity to generate profits. The equity ratio is high at 71.05%, suggesting a stable capital structure with substantial equity financing.

Cash Flow

Global Health Limited has a positive operating cash flow, consistently covering net income, which indicates effective cash management from operations. However, free cash flow growth has been volatile, with a significant decrease in 2025, highlighting potential risks in capital expenditures. The operating cash flow to net income ratio is strong, demonstrating efficient cash generation relative to earnings.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2020
Income Statement
Total Revenue	36.92B	36.92B	32.75B	21.56B	26.94B	14.29B
Gross Profit	23.61B	19.88B	17.17B	16.13B	20.69B	10.81B
EBITDA	9.32B	8.77B	8.72B	4.90B	6.78B	2.28B
Net Income	4.81B	4.81B	4.78B	1.96B	3.26B	288.05M
Balance Sheet
Total Assets	47.66B	47.66B	43.04B	31.46B	41.16B	26.94B
Cash, Cash Equivalents and Short-Term Investments	11.22B	11.22B	11.56B	5.12B	12.60B	2.89B
Total Debt	7.18B	7.18B	8.02B	11.09B	11.22B	9.31B
Total Liabilities	13.79B	13.79B	13.98B	15.30B	16.88B	13.12B
Stockholders Equity	33.86B	33.86B	29.06B	16.16B	24.28B	13.82B
Cash Flow
Free Cash Flow	0.00	1.07B	3.33B	367.87M	4.09B	960.32M
Operating Cash Flow	0.00	6.24B	6.12B	3.11B	6.45B	2.42B
Investing Cash Flow	0.00	-7.21B	-4.41B	-4.21B	-3.42B	-2.39B
Financing Cash Flow	0.00	-972.26M	-5.14B	1.60B	3.46B	-807.23M

Global Health Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1399.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDANTA, the sentiment is Positive. The current price of 1399 is above the 20-day moving average (MA) of 1362.38, above the 50-day MA of 1288.15, and above the 200-day MA of 1186.76, indicating a bullish trend. The MACD of 27.41 indicates Positive momentum. The RSI at 61.33 is Neutral, neither overbought nor oversold. The STOCH value of 62.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MEDANTA.

Global Health Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTERDM	77 Outperform	₹311.49B	94.79		0.83%	-53.19%	-94.01%
FORTIS	75 Outperform	₹691.43B	79.61		0.11%	14.04%	32.99%
MEDANTA	75 Outperform	₹376.17B	70.40		0.04%	15.42%	10.66%
KIMS	71 Outperform	₹298.38B	79.25		―	24.71%	19.17%
NH	66 Neutral	₹363.51B	46.07		0.26%	12.09%	-2.79%
METROPOLIS	64 Neutral	₹111.77B	73.07		0.71%	12.86%	10.42%
Sector *	51 Neutral	$7.81B	-0.22	-40.01%	2.29%	21.48%	-2.11%

Global Health Limited Corporate Events

Global Health Limited Expands Share Capital Through Employee Incentive Allotments

Global Health Limited has announced the allotment of 110,000 equity shares as part of its employee incentive programs. This includes 20,000 shares to an eligible employee under the ESOP 2016 Scheme and 90,000 shares to the GHL Employees Welfare Trust under the GHL LTIP 2024 Plan. The move increases the company’s paid-up share capital, reflecting its commitment to rewarding and retaining talent, which could strengthen its market position and stakeholder confidence.

Global Health Limited Expands Share Capital with New Allotment

Global Health Limited has announced the allotment of 90,000 equity shares under its Employee Stock Option Scheme 2016 and Employee Long Term Share Based Incentive Plan 2024. This move, approved by the Nomination & Remuneration Committee, increases the company’s paid-up share capital and aligns with its strategy to incentivize employees, potentially enhancing employee retention and stakeholder value.